Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
about
Toxin-based therapeutic approachesTumor infiltrating lymphocytes in ovarian cancerSuppression, subversion and escape: the role of regulatory T cells in cancer progressionA pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaSystematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factorsThe role of regulatory T cells in cancer.Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects.Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesisFocus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaFOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesionsNew roads open up for implementing immunotherapy in mesothelioma.SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γTLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence.Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell eliminationCancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.Immunosuppressive tumor microenvironment in cervical cancer patientsSynergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.Challenges and future perspectives of T cell immunotherapy in cancerA deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.Thioredoxin induces Tregs to generate an immunotolerant tumor microenvironment in metastatic melanoma.Immunotherapy of malignant brain tumors.Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administrationImmunotherapy for melanoma: current status and perspectives.Trial watch: Peptide vaccines in cancer therapyImmunogenicity of therapeutic recombinant immunotoxins.Delicate balance among three types of T cells in concurrent regulation of tumor immunity.Construction and Production of Foxp3-Fc (IgG) DNA Vaccine/Fusion ProteinLimited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs.Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trialShifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection.Immunotherapy opportunities in ovarian cancer.Immunoregulatory T cells: role and potential as a target in malignancy.Immunotoxins: the role of the toxin.
P2860
Q27013664-35F9E7B0-6D38-4475-8318-E58C03A8C1F5Q27021878-336949AA-2955-4679-95A8-A5DD3976AD68Q27026151-CE8DAA0B-372A-4F8B-8F9D-F9195D3519A5Q28731711-72077778-B4BD-4C38-BF46-C0EA371550FDQ33488520-0BD73EFA-A990-4EAF-A1AA-554B8E44B0CAQ33631986-CF865AA8-467B-4169-8E31-5F5C3FDA3E9BQ33907691-994D1FDB-DA0E-43D7-AFF3-97389624C6A0Q33923717-AF9E02A0-4BCF-463C-9F13-B3A8349DD80AQ33930139-2AC5933F-AA2B-4CAC-814F-ED0B6B55D815Q34111789-5F1610D9-11FB-4983-9E63-26BF1AF2B956Q34197717-B66807A0-5F6E-4251-B6F5-044768432B05Q34331993-87F34AC3-F6E6-44FB-B0FC-536A0044DE02Q34369526-E266E119-BDC7-4125-8060-9E65D87DA59EQ34880391-4C36AAFC-3EAC-48B0-A39C-F0770542C41DQ34898280-E14D58F9-4315-4614-BD4A-7BC9834FA03CQ35012887-DC4DF3A8-B0CF-41E6-9223-3AF0E246ADB4Q35033249-F9E1945C-797E-4ABC-8994-0DA77449449EQ35230663-0A13D2C3-65E3-4907-A5FF-1A3C529F780DQ35603131-0806A2C6-8AE7-4585-8314-75D31FA916F6Q35653164-1686AA05-271F-4691-85FB-FE8698D7EBAEQ35843507-1549F882-4884-4323-9729-E3E37D89DF76Q35911544-D6C6066E-C507-4A02-8DF9-0498EA5DC262Q36060244-B8E3621D-172D-4D47-9413-C8F24BC47C21Q36162929-E8EF3A13-E05E-490E-A6D5-C6006CD8B206Q36344582-0AF17B86-99BC-4ACB-ABFD-0F4E12736E53Q36453216-EA528232-197F-4E23-A548-BD8C7DF4AD38Q36476100-D0DA3C08-58A6-47F9-9955-642027B58F44Q36593468-554D1E8C-F17F-4941-A17E-7F71424469A7Q36755513-E04F9B97-EB70-4EEB-A53A-07A5596B4451Q36828834-A9A6891F-A123-4025-955D-07DC5C8C9EEFQ36853440-38703179-64F7-4344-B307-6592D13D338CQ36952541-367ED23E-DC46-4583-82D2-FF815892631BQ37000445-A2CB2305-69F7-457B-9799-ABB29BD38374Q37017085-F3839C87-DED6-40FB-A8BC-7D9AF14EEF6EQ37024271-18242F1F-498F-4CB7-83F5-39B82F709B9BQ37055402-1B91780A-D28A-4DB0-AB19-23A6E6E96D89Q37071100-82247F69-319F-441C-A113-69F1B39AC511Q37086013-0D29FA2E-8DEF-4E2C-B77F-5B70B0906D76Q37123810-E5AADEB5-CAC6-4788-AF91-F773302B4BA3Q37139525-99A926D6-283A-4816-A2A9-C357FA0A9187
P2860
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Administration of a CD25-direc ...... in regulatory T cells in vivo.
@ast
Administration of a CD25-direc ...... in regulatory T cells in vivo.
@en
Administration of a CD25-direc ...... in regulatory T cells in vivo.
@nl
type
label
Administration of a CD25-direc ...... in regulatory T cells in vivo.
@ast
Administration of a CD25-direc ...... in regulatory T cells in vivo.
@en
Administration of a CD25-direc ...... in regulatory T cells in vivo.
@nl
prefLabel
Administration of a CD25-direc ...... in regulatory T cells in vivo.
@ast
Administration of a CD25-direc ...... in regulatory T cells in vivo.
@en
Administration of a CD25-direc ...... in regulatory T cells in vivo.
@nl
P2093
P2860
P1476
Administration of a CD25-direc ...... in regulatory T cells in vivo.
@en
P2093
Aloisio Felipe-Silva
Catherine Levy
Daniel J Powell
Donald E White
Ira Pastan
Maria J Merino
Mojgan Ahmadzadeh
Robert J Kreitman
Sharon Mavroukakis
Steven A Rosenberg
P2860
P304
P356
10.4049/JIMMUNOL.179.7.4919
P407
P577
2007-10-01T00:00:00Z